CSBio CSBio

X
[{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angelini Pharma and Sunovion Pharmaceutical Europe Receive EMA Approval for Latuda for the Treatment of Adolescent Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Angelini Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.

            Lead Product(s): Lurasidone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Latuda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY